Anti-myelin antibodies (anti-MOG and anti-MBP) have long been targets of interest in MS research, and some foci of interest have been the relevance of anti-MBP antibodies as a possible cause of MS, as well as anti-myelin antibodies as markers for severity of disease or as markers for risk of progression. This evidence concerns the gene MBP and myeloid sarcoma.